Finanzas de Avadel Pharmaceuticals PLC (AVDL)AVDLAvadel Pharmaceuticals PLC

Avadel Pharmaceuticals PLC (AVDL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Vazculep, accounting for 48.7% of total sales, equivalent to $4.92M. Other significant revenue streams include Akovaz and Bloxiverz. Understanding this composition is critical for investors evaluating how AVDL navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Avadel Pharmaceuticals PLC maintains a gross margin of 93.05%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -9.76%, while the net margin is 0.03%. These profitability ratios, combined with a Return on Equity (ROE) of -0.32%, provide a clear picture of how effectively AVDL converts its operational activities into shareholder value.

In the context of the broader market, AVDL competes directly with industry leaders such as OGN and HRMY. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, AVDL's gross margin of 93.05% stands against OGN's 54.36% and HRMY's 75.81%. Such benchmarking helps identify whether Avadel Pharmaceuticals PLC is trading at a premium or discount relative to its financial performance.

In Q3 2025, revenue grew by 54.86% YoY to $77.47 million, but net income dropped to $20,000 (-100.76% YoY), and EPS fell to 0 (-100.00% YoY). Gross margin improved to 93.05%, up 6.10% YoY.